Quality assurance and Guidance Executive sign off dates for: Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management In development [GID-NG10091]

The request was successful.

Dear National Institute for Health and Care Excellence,

According to NICE document: Developing NICE guidelines: the manual, Process and methods [PMG20] Last updated: 15 October 2020

11.1 Quality assurance of the guideline
After changes agreed by the committee have been made to the guideline in response to consultation comments from registered stakeholders, the guideline is reviewed by NICE staff with responsibility for guideline quality assurance. They check that the changes made to the guideline are appropriate and that the developer has responded appropriately to the registered stakeholders' comments. Further changes to the guideline may be needed; the developer continues to maintain an audit trail of all the changes. The NICE Pathway (everything NICE says on a topic in an interactive flowchart) and any supporting resources are amended in line with any changes to the guideline. These also undergo quality assurance and are signed off within NICE.

11.2 Signing off the guideline
NICE's Guidance Executive considers and approves guidelines for publication on behalf of the NICE Board. The Guidance Executive is made up of NICE executive directors, centre directors and the communications director. When considering a guideline for publication, the Guidance Executive reviews a report from NICE staff with responsibility for guideline quality assurance.

Please provide the following information under the Act:

1) The date on which Quality assurance for guideline: Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management In development [GID-NG10091] was signed off.

2) The date on which the NICE Pathway (everything NICE says on a topic in an interactive flowchart) and any supporting resources were signed off for quality assurance.

3) The date on which NICE's Guidance Executive signed off guideline GID-NG10091.

Yours faithfully,

Suzy Chapman

Dear National Institute for Health and Care Excellence,

This request was marked as "Delivered" but I received no acknowledgement from NICE.

A response is due by October 01, 2021 (tomorrow).

Could you please acknowledge receipt of my request and confirm by what date a response is expected?

Yours faithfully,

Suzy Chapman

Dear National Institute for Health and Care Excellence,

Re: FOI request submitted on 03 September 2021 and marked as Delivered.

A response has been delayed. A response was expected by 01 October 2021.

No Acknowledgement has been received for this request.

Request subject: Quality assurance and Guidance Executive sign off dates for: Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management In development [GID-NG10091].

Request URL on WhatDoTheyKnow website: https://www.whatdotheyknow.com/request/q...

Server details are available from the link on the WhatDoTheyKnow website.

Request text:

Dear National Institute for Health and Care Excellence,

According to NICE document: Developing NICE guidelines: the manual, Process and methods [PMG20] Last updated: 15 October 2020

11.1 Quality assurance of the guideline
After changes agreed by the committee have been made to the guideline in response to consultation comments from registered stakeholders, the guideline is reviewed by NICE staff with responsibility for guideline quality assurance. They check that the changes made to the guideline are appropriate and that the developer has responded appropriately to the registered stakeholders' comments. Further changes to the guideline may be needed; the developer continues to maintain an audit trail of all the changes. The NICE Pathway (everything NICE says on a topic in an interactive flowchart) and any supporting resources are amended in line with any changes to the guideline. These also undergo quality assurance and are signed off within NICE.

11.2 Signing off the guideline
NICE's Guidance Executive considers and approves guidelines for publication on behalf of the NICE Board. The Guidance Executive is made up of NICE executive directors, centre directors and the communications director. When considering a guideline for publication, the Guidance Executive reviews a report from NICE staff with responsibility for guideline quality assurance.

Please provide the following information under the Act:

1) The date on which Quality assurance for guideline: Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management In development [GID-NG10091] was signed off.

2) The date on which the NICE Pathway (everything NICE says on a topic in an interactive flowchart) and any supporting resources were signed off for quality assurance.

3) The date on which NICE's Guidance Executive signed off guideline GID-NG10091.

Yours faithfully,

Suzy Chapman
--------------------------------------------------------

I should be pleased if you will respond with confirmation of the status of this 03 September request.

Yours faithfully,

Suzy Chapman

National Institute for Health and Care Excellence (NICE), National Institute for Health and Care Excellence

1 Attachment

Dear Suzy,

 

I am very sorry that you have not received an acknowledgement of your
request for information. This was an oversight on our part and I apologise
for our error.

 

We have received an unexpectedly high number of similar overlapping
requests. The complexity of processing them alongside reduced capacity
within the small team that handles Freedom of Information requests at
NICE, has meant we have needed to request advice from our external legal
advisers. This has caused additional delay in terms of providing a
response.

 

I would like to assure you that your request is being considered and we
will provide you with a response as soon as we can.

 

Kind regards,

 

Helen

 

Helen Finn (she/her)

Senior communications manager (enquiries)

National Institute for Health and Care Excellence

Level 1A, City Tower | Piccadilly Plaza | Manchester | M1 4BT | United
Kingdom

Tel: 0300 323 0140

Web: [1]http://nice.org.uk

 

[2]Find out more about the new NICE strategy on our website

 

show quoted sections

Dear National Institute for Health and Care Excellence (NICE),

Thank you, Helen, for acknowledging receipt of this request which was submitted on 3 September, 2021 and had been due for fulfilment on 1 October, 2021, and is now 10 days overdue.

I look forward to receiving the information requested.

Yours sincerely,

Suzy Chapman

Dear National Institute for Health and Care Excellence (NICE),

Dear Helen,

Tomorrow this FOI request will be 21 days overdue. I shall be pleased if this brief and straightforward request for information can be fulfilled without undue delay and a revised date by which a response can be expected can now be provided.

Yours sincerely,

Suzy Chapman

Dear National Institute for Health and Care Excellence (NICE),

Dear Helen,

Tomorrow this FOI request will be 28 days overdue.

I shall be pleased if this brief and straightforward request for information can be fulfilled without further delay and a revised date by which a response can be expected under the ACT can be provided.

Yours sincerely,

Suzy Chapman

National Institute for Health and Care Excellence (NICE), National Institute for Health and Care Excellence

Dear Suzy

 

Reference: EH-317847

 

FREEDOM OF INFORMATION ACT 2000

 

I am sorry for the delay in responding to your request for information.
Please find the response to your questions below:

 

 1. The date on which Quality assurance for guideline: Myalgic
encephalomyelitis (or encephalopathy)/chronic fatigue syndrome:
diagnosis and management In development [GID-NG10091] was signed off.

Response: The guideline was signed off on 08 July 2021.

 

 2. The date on which the NICE Pathway (everything NICE says on a topic in
an interactive flowchart) and any supporting resources were signed off
for quality assurance.

Response: Information not held. A NICE Pathway is an alternative
representation of other NICE guidance, the content is the same. The
content was signed off under 1 and 3.

 

 3. The date on which NICE's Guidance Executive signed off guideline
GID-NG10091.

Response: NICE’s guidance executive approved the guideline for embargoed
release on 30 July 2021.

 

If you have any questions on this response you are welcome to email the
enquiry handling team at [1][NICE request email].

 

If you are unhappy with this response and want an internal review of how
we handled your request, you must write to us within 40 working days of
our response. Send your request to: Associate Director, Corporate Office,
National Institute for Health and Care Excellence, 2nd Floor, 2 Redman
Place, London, E20 1JQ or email: [2][email address]. When we
receive your request, we will send you an acknowledgement within 5 working
days.

 

The Associate Director, Corporate Office, will review your complaint and
send you a full reply usually within 20 working days. If you are
dissatisfied with the outcome of this review, you can apply directly to
the Information Commissioner for a decision at: The Information
Commissioner’s Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9
5AF.

 

Kind regards

 

Helen

 

 

Helen Finn (she/her)

Senior communications manager (enquiries)

National Institute for Health and Care Excellence

Level 1A, City Tower | Piccadilly Plaza | Manchester | M1 4BT | United
Kingdom

Tel: 44 (0)300 323 0141

Web: [3]http://nice.org.uk

 

 

 

show quoted sections